PCN259 Should health state utility values (HSUVS) in cancer immunotherapies (IOS) be analyzed by time to death (TTD) or progression status? Results of a simulation study

Hatswell, A.J., Bullement, A. orcid.org/0000-0001-7091-0972, Schlichting, M. et al. (1 more author) (2019) PCN259 Should health state utility values (HSUVS) in cancer immunotherapies (IOS) be analyzed by time to death (TTD) or progression status? Results of a simulation study. In: Value in Health. ISPOR 2019 : Rapid. Disruptive. Innovative: A New Era in HEOR, 18-22 May 2019, New Orleans, LA, USA. Elsevier BV , S105-S105.

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2019 Published by Elsevier Inc.
Dates:
  • Published (online): 24 June 2019
  • Published: May 2019
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield)
Depositing User: Symplectic Sheffield
Date Deposited: 10 Nov 2021 14:21
Last Modified: 10 Nov 2021 14:21
Status: Published
Publisher: Elsevier BV
Refereed: Yes
Identification Number: https://doi.org/10.1016/j.jval.2019.04.380

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export

Statistics